Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumour-burdened lymph nodes after intravenous and subcutaneous administration in rats by Kaminskas, Lisa et al.
This is the author’s version of a work that was submitted/accepted for pub-
lication in the following source:
Kaminskas, Lisa M., McLeod, Victoria M., Ascher, David B., Ryan, Gemma
M., Jones, Seth, Haynes, John M., Trevaskis, Natalie L., Chan, Linda
J., Sloan, Erica K., Finnin, Benjamin A., Williamson, Mark, Velkov, Tony,
Williams, Elizabeth D., Kelly, Brian D., Owen, David J., & Porter, Christo-
pher J.H.
(2015)
Methotrexate-conjugated PEGylated dendrimers show differential patterns
of deposition and activity in tumour-burdened lymph nodes after intra-
venous and subcutaneous administration in rats.
Molecular Pharmaceutics, 12(2), pp. 432-443.
This file was downloaded from: http://eprints.qut.edu.au/80215/
c© Copyright 2014 American Chemical Society
Notice: Changes introduced as a result of publishing processes such as
copy-editing and formatting may not be reflected in this document. For a
definitive version of this work, please refer to the published source:
http://doi.org/10.1021/mp500531e
1 
 
Methotrexate-conjugated PEGylated dendrimers show differential patterns 
of deposition and activity in tumour-burdened lymph nodes after 
intravenous and subcutaneous administration in rats 
Lisa M Kaminskas
a*†
, Victoria M McLeod
a†
, David B Ascher
b
, Gemma M Ryan
a
, Seth Jones
a
, John 
M Haynes
c
, Natalie L Trevaskis
a
, Linda J Chan
a
, Erica K Sloan
c
, Benjamin A Finnin
c
, Mark 
Williamson
d
, Tony Velkov
a
, Elizabeth D Williams
e
, Brian D Kelly
f
, David J Owen
f
, Christopher JH 
Porter
a*
 
 
a
 Drug Delivery Disposition and Dynamics Group, Monash Institute of Pharmaceutical Sciences, 
Monash University, Parkville, VIC, Australia, 3052 
b
 ACRF Rational Drug Discovery centre and Biota Structural Biology Laboratory, St Vincent’s 
Institute for Medical Research, Fitzroy, VIC, Australia, 3000 
c
 Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, 
Parkville, VIC, Australia, 3052 
d
 Gribbles Veterinary Pathology, Clayton, VIC, Australia, 3168 
e
 Australian Prostate Cancer Research Centre, Institute of Health and Biomedical Innovation, 
Queensland University of Technology, Brisbane, QLD, Australia, 4102; Department of Surgery, St 
Vincent’s Hospital, The University of Melbourne, Fitzroy, VIC, Australia, 3065; Monash Institute 
of Medical Research, Monash University, Clayton, VIC, Australia, 3168 
f
 Starpharma Pty Ltd, Melbourne, VIC, Australia, 3004. 
 
† these authors contributed equally to this manuscript 
 
Keywords: methotrexate, lymphatic, lymphatic metastasis, pharmacokinetics, subcutaneous, 
dendrimer 
 
*Corresponding authors: 
 
Dr Lisa M Kaminskas 
Monash Institute of Pharmaceutical Sciences 
381 Royal Pde, Parkville 
VIC, Australia, 3052 
Ph. +61 3 9903 9522 
Fax. +61 3 9903 9583 
Email. lisa.kaminskas@monash.edu 
Prof Christopher JH Porter 
Monash Institute of Pharmaceutical Sciences 
381 Royal Pde, Parkville 
VIC, Australia, 3052 
Ph. +61 3 9903 9649 
Fax. +61 3 9903 9583 
Email. chris.porter@monash.edu 
Page 1 of 32
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2 
 
 
For table of contents use only: 
 
Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and 
activity in tumour-burdened lymph nodes after intravenous and subcutaneous administration 
in rats 
 
Lisa M Kaminskas
a*†
, Victoria M McLeod
a†
, David B Ascher
b
, Gemma M Ryan
a
, Seth Jones
a
, John 
M Haynes
c
, Natalie L Trevaskis
a
, Linda J Chan
a
, Erica K Sloan
c
, Benjamin A Finnin
c
, Mark 
Williamson
d
, Tony Velkov
a
, Elizabeth D Williams
e
, Brian D Kelly
f
, David J Owen
f
, Christopher JH 
Porter
a*
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 2 of 32
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
3 
 
 
Abstract: 
 
The current study sought to explore whether the subcutaneous administration of lymph-targeted 
dendrimers, conjugated with a model chemotherapeutic (methotrexate, MTX), was able to enhance 
anticancer activity against lymph node metastases. The lymphatic pharmacokinetics and antitumour 
activity of PEGylated polylysine dendrimers conjugated to MTX [D-MTX(OH)] via a tumour-labile 
hexapeptide linker was examined in rats and compared to a similar system where MTX was α-
carboxyl O-tert-butylated [D-MTX(OtBu)]. The latter has previously been shown to exhibit longer 
plasma circulation times. D-MTX(OtBu) was well absorbed from the subcutaneous injection site 
via the lymph, and 3 to 4%/g of the dose was retained by sentinel lymph nodes. In contrast, D-
MTX(OH) showed limited absorption from the subcutaneous injection site, but absorption was 
almost exclusively via the lymph. The retention of D-MTX(OH) by sentinel lymph nodes was also 
significantly elevated (approximately 30% dose/g). MTX alone was not absorbed into the lymph. 
All dendrimers displayed lower lymph node targeting after intravenous administration. Despite 
significant differences in the lymph node retention of D-MTX(OH) and D-MTX(OtBu) after 
subcutaneous and intravenous administration, the growth of lymph node metastases was similarly 
inhibited. In contrast, the administration of MTX alone did not significantly reduce lymph node 
tumour growth. Subcutaneous administration of drug-conjugated dendrimers therefore provides an 
opportunity to improve drug deposition in downstream tumour-burdened lymph nodes. In this case, 
however, increased lymph node biodistribution did not correlate well with antitumour activity, 
possibly suggesting constrained drug release at the site of action.  
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Introduction: 
 The metastatic spread of solid tumours is responsible for approximately 90% of all cancer-
related deaths.
1
 Metastasis may occur either via the blood (leading to secondary tumour 
development in target organs such as the lungs, bone marrow and brain) or via the lymph (leading 
initially to the development of tumours in the sentinel lymph nodes draining the primary tumour). 
Metastases are commonly treated via a combination of surgical removal and chemo- and radiation-
therapies.
2
 The surgical removal of tumour-bearing sentinel lymph nodes (lymphadenectomy), 
however, has only limited success in preventing the subsequent spread of the cancer.
3-6
 This has 
been suggested to reflect the realisation that 1) cancer cells that have passed beyond the sentinel 
nodes or are in transit to downstream lymph nodes are not removed during lymphadenectomy, 2) an 
intact lymphatic system may enhance the eradication of metastasising cancer cells
7
 and therefore 
lymph node removal may inhibit metastatic clearance, and 3) post lymphadectomy, metastatic 
pathways via the blood remain intact and are promoted by metastatic cancers releasing factors that 
prime key target organs.
8, 9
 As such, the potential for ongoing metastatic spread remains. Whilst 
post-surgical chemotherapy has the potential to target and kill cancer cells that have metastasised 
beyond the sentinel lymph nodes, small molecule cancer chemotherapy drugs display limited 
lymphatic availability after intravenous (IV) and subcutaneous (SC) administration.
10
 The combined 
treatment of lymphatic metastases with surgery and lymph-targeted chemotherapeutic 
nanomedicines may therefore improve outcomes for cancers that metastasise via the lymph. 
 Several liposomal, nanoparticulate and polymeric nanomedicines are currently in the clinic 
or in clinical trials as tumour-targeted drug delivery systems. These are almost exclusively 
administered IV to enhance drug exposure to solid tumours via the enhanced permeation and 
retention (EPR) effect.
11-13
 Previous work in our laboratory, however, has shown that long 
circulating PEGylated nanomaterials such as PEGylated liposomal doxorubicin (100 nm, marketed 
as Doxil® or Caelyx®) and a 56 kDa doxorubicin-loaded PEGylated dendrimer (12 nm) readily 
access the lymph after SC delivery and might assist in gaining access to sites of lymphatic 
metastasis.
10
 SC administration at the site of a primary tumour offers the potential advantage of 
higher drug concentrations in the lymphatics draining the injection site (when compared to IV 
administration), selective targeting to downstream lymph nodes, and reduced drug concentrations in 
blood (and therefore reduced systemic toxicity).
14
 We have previously shown that PEGylated 
dendrimers larger than approximately 20 kDa are preferentially absorbed from interstitial injection 
sites via the lymph and are retained by sentinel lymph nodes in a size dependent manner (where 
larger dendrimers display better lymph node retention than smaller dendrimers).
15
 In this study, a 12 
nm doxorubicin-conjugated PEGylated polylysine dendrimer was shown to target the lymphatics 
after SC administration and to be retained within lymph nodes more effectively than either a 100 
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nm PEGylated liposomal formulation or a simple solution formulation of doxorubicin.
10
 This 
suggests that dendrimers have the potential to enhance drug exposure to lymph node-resident 
metastases when compared to commercially available solution and liposomal formulations.  
In this previous study, retention of the doxorubicin-conjugated dendrimer in lymph nodes 
was suggested to occur via physical entrapment of the polymer within lymph nodes. This strategy 
may be further enhanced by employing drug carriers that target lymph node-resident 
macrophages.
16-19
 This can be accomplished via the conjugation of macrophage targeting ligands, 
such as mannose, to the carrier surface, or by increasing surface charge to promote recognition of 
the carrier by both the lymph node parenchyma and lymph node-resident macrophages.  
In this regard, we have recently characterised the IV pharmacokinetics of two 69-71 kDa 
methotrexate (MTX)-conjugated PEGylated polylysine dendrimers (Figure 1) that display 
significant differences in charge, macrophage targeting and pharmacokinetic and biodistribution 
behaviour.
20
 Conjugation of MTX to the α-amino group on surface lysine residues via a matrix 
metalloproteinase cleavable PVGLIG (Pro-Val-Gly-Leu-Ile-Gly) linker led to rapid clearance from 
plasma via the organs of the mononuclear phagocyte system (MPS), in particular the liver. The 
scaffold was then biodegraded and monomeric lysine liberated, redistributed to the liver and 
incorporated into protein resynthetic pathways. As a result of rapid plasma clearance, however, the 
D-MTX(OH) dendrimer did not show efficient tumour targeting and chemotherapeutic activity.
20
 In 
contrast, capping the free carboxyl group of MTX with an OtBu functionality, reduced MPS 
clearance and increased the plasma half-life of D-MTX(OH). The OtBu dendrimer subsequently 
showed efficient uptake into tumours and improved antitumour activity when compared to a 
solution formulation of MTX.
20
  
Although D-MTX(OH) did not show anti-cancer activity in a mouse xenograft model after 
IV delivery in the previous study
20
, the enhanced affinity of this dendrimer for the cells of the MPS 
suggests the possibility of enhanced uptake by macrophages in lymph nodes draining an SC 
injection site, and improved chemotherapeutic activity after local administration. In the present 
study, we therefore sought to examine this hypothesis and to compare the patterns of lymphatic 
disposition and antitumour activity of the two MTX-conjugated dendrimer constructs after SC and 
IV administration in rats. In vivo activity was expected to be a function of biodistribution towards 
the tumour-burdened lymph node, disposition of the drug within the node and efficient liberation of 
drug within the tumour. The cancer model employed involved the footpad injection of rat mammary 
MAT 13762 IIIB carcinoma cells into syngeneic F344 rats to generate secondary lymphatic 
metastases in the popliteal lymph node of fully immunocompetent rats. The cellular targets and 
regional distribution of D-MTX(OH) in lymph nodes was also examined via confocal fluorescence 
microscopy and flow cytometry.  
Page 5 of 32
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
6 
 
 
Methods: 
Materials & Reagents 
The hexapeptide (PVGLIG) was purchased as a custom synthesis from EZbiolab (IN, USA). 
Unlabeled lysine for synthesis was from Bachem (Bunbendorf, Switzerland). (L)-(4,5-
3
H)-Lysine (1 
mCi/mL) was purchased from MP Biomedicals (CA, USA). Monodisperse NHS-PEG1100 was 
obtained from Quanta BioDesign, Ltd. (USA). The NHS ester of Atto488 was obtained from Perkin 
Elmer (MA, USA). Methotrexate [3’,5’,7’-
3
H] sodium salt was from American Radiolabelled 
Chemicals (St. Louis, MO, USA). Medical grade polyethylene, polyvinyl and silastic tubing (0.58 
mm internal diameter, 0.96 mm external diameter) were obtained from Microtube Extrusions 
(NSW, Australia). RPMI Medium 1640, Dulbecco’s Phosphate Buffered Saline (DPBS) without 
CaCl2 or MgCl2, fetal bovine serum (FBS), glutaMAX, penicillin/streptomycin, and 0.25% trypsin-
EDTA were purchased from Gibco® (Invitrogen, VIC, Australia). Culture flasks and plates were 
from Corning (NY, USA). Microplates were from Greiner Bio-One (Biolab, VIC, Australia). 
Methotrexate, collagenase (type IV) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT) were purchased from Sigma (NSW, Australia). pmCherry-C1 vector was purchased 
from Clontech (Mountain View, CA). Lipofectamine™ LTX and PLUS™ Reagent kit were 
purchased from Invitrogen (VIC, Australia). G-418 Solution (neomycin) was purchased from Roche 
(NSW, Australia). Soluene-350 tissue solubiliser and Irga Safe Plus liquid scintillation cocktail 
were purchased from Packard Biosciences (Meriden, CT). Buffer reagents (analytical reagent 
grade) were from Ajax Finechem Pty Ltd. (NSW, Australia). Dispase, deoxyribonuclease I, ACK 
Lysis Buffer and SYTOX Blue dead cell stain were from Invitrogen (VIC, Australia). GentleMACS 
C-tubes and M-tubes were obtained from Miltenyi Biotech Australia (NSW, Australia). All 
antibodies and BD Trucount tubes were purchased from Becton Dickinson (Bedford, MA). All 
other reagents were AR grade. 
 
Synthesis of dendrimers 
The synthesis and characterisation of the tritiated G5 dendrimer constructs containing a 
surface of 50% PEG1100 and 50% underivatised primary amine or 50% cleavable hexapeptide 
(PVGLIG) methotrexate have been previously described.
20, 21
 Briefly, generation 5 poly-L-lysine 
scaffolds were conjugated with methotrexate at surface α-amino groups via a PVGLIG linker and 
with PEG1100 at surface ε-amino groups (Figure 1). Methotrexate contained either an OtBu-
protecting group at the α-carboxyl (to give D-MTX(OtBu)) or remained unconjugated (to give D-
MTX(OH)). D-MTX(OH) and D-MTX(OtBu) contained 17% MTX per weight (equivalent to 
approximately 26 MTX molecules per dendrimer). A control dendrimer that represented a possible 
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product of peptide cleavage and MTX liberation (where a partial positive charge would be 
conferred on the dendrimer; D-NH2) was similarly PEGylated with PEG1100 at surface ε-amino 
groups, but remained unconjugated at ε-amino groups (to give a 50:50 surface of PEG and primary 
amino groups). In addition, a G5 dendrimer containing 50% PEG1100 and 50% PVGLIG where the 
surface proline was conjugated with glutamic acid to present a carboxylate (D-COOH) was 
synthesised and characterised as described in the supporting information. This provided a dendrimer 
with a partial anionic charge to serve as a control for D-MTX(OH)) For in vivo/in vitro imaging 
studies, D-MTX(OH) was prepared with 1 or 2 Atto488 fluorescent labels. This was achieved by 
adding 2 moles of NHS-Atto488 per mole of dendrimer scaffold during PEG conjugation. 
 
Animals 
Male Sprague Dawley (SD) rats (270-320 g) were supplied by Monash Animal Services 
(VIC, Australia). Female F344 rats (8-10 weeks) were supplied by Animal Resources Centre (WA, 
Australia). Animals were maintained on a 12 h light dark cycle and were provided with water at all 
times. Food was withheld only after surgical placement of cannulas and for 8 hours after dosing. All 
animal experimentation was approved by the institutional Animal Ethics Committee. 
 
Cell Culture 
Rat mammary MAT 13762 IIIB carcinoma cells (MAT) were purchased from ATCC 
(Manassas, VA) and were transfected with a vector encoding the fluorescent protein mCherry-C1 
for imaging studies as described in the supporting information (supporting information available free 
of charge via the Internet at http://pubs.acs.org). Murine RAW-264.7 macrophages (RAW) were a 
kind donation by Dr Julian Quinn (Prince Henry’s Institute, Melbourne). Cells were propagated in 
RPMI media supplemented with 10% FBS, 1% Glutamax and 100 U penicillin/ 100µg streptomycin 
and maintained in a 37°C humidified environment and 5% CO2. MAT cells were passaged using 
trypsin-EDTA and RAW cells via a mechanical cell scraping method. All cells were used between 
passages 5 and 10 and tested negative for mycoplasma contamination. The cytotoxicity of the 
dendrimers and unconjugated methotrexate were tested against MAT and RAW cancer cells as well 
as primary rat peritoneal macrophages and rat lymphocytes that were obtained from thoracic duct 
lymph as described in the supporting information. 
 
Determination of lymphatic pharmacokinetics in Sprague Dawley rats 
Pharmacokinetic studies were conducted in parallel subsets of animals (n=3-4) for each 
dendrimer and free methotrexate to give three data sets: 1) an IV dosed control (non-lymph 
cannulated) group, 2) a SC dosed control (non-lymph cannulated) group and 3) a SC dosed thoracic 
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lymph duct cannulated group as previously described.
15
 Rats were anaesthetised using isoflurane 
and cannulated via the carotid artery for blood sample collection in all groups and the right jugular 
vein for IV dosing or saline infusion in IV control and SC lymph cannulated groups respectively, as 
previously described
22
. The SC lymph group additionally had cannulas implanted in the thoracic 
lymph duct for continuous lymph collection using previously reported surgical procedures.
15
 
Following overnight recovery, rats were administered 5 mg/kg dendrimer or MTX (equating to 0.5-
1 µCi of 
3
H-dendrimer or 2-4 µCi 
3
H-methotrexate) in 1 ml saline over a 2 minute infusion via the 
jugular vein cannula, or in 500 µl/kg saline subcutaneously into the right hindlimb as previously 
described.
15
  
Whole blood (0.15 ml) was collected into heparinised (10 U) Eppendorf tubes and 
centrifuged at 3500 g for 5 mins to obtain plasma. Plasma samples were mixed with 1 mL Irga Safe 
Plus and analysed on a Packard Tri-carb liquid scintillation counter for determination of 
3
H content 
as previously described.
22
 Lymph fluid collected at 1-12 hour intervals was mixed with at least 2 
volumes of Irga Safe Plus and analysed as above. Rats administered methotrexate and rats bearing 
indwelling thoracic lymph duct cannulas were euthanized 30 h after dosing. Rats administered D-
MTX(OH) were euthanized 72 h after dosing and rats administered D-MTX(OtBu), D-COOH or D-
NH2 were euthanized after 120 h. After termination of non-lymph cannulated rats, major organs 
(liver, lungs, heart, spleen, pancreas, kidneys) and lymph nodes (popliteal and inguinal nodes on the 
ipsilateral side to dosing and iliac nodes) were collected from non-lymph cannulated animals and 
analysed for 
3
H content (see supporting information). Size exclusion chromatography (SEC) was 
also used to identify the radiolabelled species present in plasma and lymph samples collected from 
SC dendrimer dosed animals as described in the supporting information. 
 
Size exclusion chromatography of plasma and lymph samples after SC administration of 
methotrexate-conjugated dendrimers in rats 
Size exclusion chromatography was used to identify the radiolabelled species present in 
plasma and lymph samples collected from SC dosed dendrimers, with the exception of D-
MTX(OH) which was undetectable in plasma following SC administration.  Samples were diluted 
1:1 in mobile phase where tritium counts were sufficiently high and 100-200 µl volumes injected 
onto a size exclusion column as previously described
20
. Chromatographic conditions were as 
reported previously
20
 with samples eluted on a Superdex 200 column to allow better separation of 
the larger molecular weight (MW) species present in lymph and plasma. To identify whether the 
MTX-dendrimers bind to components of the plasma or lymph to form high molecular weight 
products, solutions of dendrimer diluted only in phosphate buffered saline (PBS) were compared to 
dilutions in plasma or lymph and incubation at 37°C for 1 h prior to injected onto the column. 
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Rat model of lymph-metastatic cancer 
Lymphatic metastases were established in the left popliteal lymph node of syngeneic female 
F344 rats by injecting 1x10
5
 MAT cells in 50 µl DPBS SC into the left footpad. Primary tumour 
growth in the footpad was evidenced initially by swelling, and later by the formation of a solid 
palpable mass. This led to the establishment of micrometastases in the ipsilateral popliteal lymph 
node within 12 days, and this was confirmed by the presence of cancer cells expressing mCherry 
fluorescent protein in the popliteal lymph node by laser scanning confocal fluorescence microscopy 
(Nikon® A1-R, Japan). Primary and secondary tumour growth, walking, rearing behaviour and 
body weight were monitored every 2 days. As a result of the growth of the footpad tumour 
eventually impacting on the ability to walk and rear, rats were euthanized 3 weeks after injection of 
cells.  
 
Biodistribution of dendrimers to tumour and non-tumour burdened lymph nodes 
The biodistribution of SC administered MTX and MTX-dendrimers in non-tumour burdened 
lymph nodes was determined as described above in male SD rats. In addition, the biodistribution of 
MTX and MTX-dendrimers into popliteal lymph nodes bearing palpable MAT metastases was 
assessed in female F344 rats after SC and IV administration. Lymph node metastases were 
established in the left popliteal lymph node as described above. Once the popliteal nodes reached a 
palpable size of approx 3 mm in diameter, rats were administered 5 mg/kg of 
3
H-labelled MTX, D-
MTX(OH), D-MTX(OtBu) or D-NH2 SC (via the inner ipsilateral heel in a volume of 500 µl/kg 
saline) or IV (via a lateral tail vein in a volume of 500 µl saline). Rats were sacrificed 3 days later 
and popliteal lymph nodes were removed, weighed and analysed for 
3
H content as previously 
described.
15
 Statistical analysis was performed using two-way ANOVA to compare cancerous and 
non-cancerous nodes, dosing route and dendrimer treatment. 
 
Confocal microscopy and & flow cytometric assessment of D-MTX(OH) distribution and cell 
targets in tumour-burdened lymph nodes 
In order to identify the cellular targets for D-MTX(OH) within tumour-burdened lymph 
nodes, an additional group of rats were injected via the footpad with mCherry-expressing MAT 
cells that were generated according to the methods described in the supporting information. Twelve 
days after injection of MAT cells, rats were given 0.5 mg Atto488-labelled D-MTX(OH) SC into 
the heel ipsilateral to tumour growth. Rats were euthanised 3 days later and ipsilateral popliteal and 
inguinal lymph nodes, the iliac node and contralateral popliteal lymph nodes were removed. Nodes 
were initially imaged on a Caliper IVIS II fluorescence imager (Perkin Elmer) to identify the 
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drainage pattern from the SC injection site and the extent of D-MTX(OH) retention in the different 
nodes. Fresh ipsilateral popliteal lymph node sections (150 µm) were then cut using a vibratome 
and sections imaged on a glass microscope slide at 4X magnification using a laser scanning 
confocal microscope to visualise the regional distribution of D-MTX(OH) within the node. The 
remainder of the lymph nodes were dissociated via enzymatic digestion to create single cell 
suspensions for flow cytometry analysis according to the following procedure.  
 
Lymph nodes were enzymatically dissociated in 2.5 ml RPMI (with RPMI containing 2.5% 
serum-containing, 1 mg/ml collagenase IV, 0.5 mg/mL dispase, 250 U/ml DNaseI) at 37°C for 40-
60 min followed by mechanical dissociation using the gentleMACS™ dissociator (C-tube 
programme, Miltenyi Biotech). Cell suspensions were diluted 1:1 with PBS containing 4 mM 
EDTA/4% FBS and passed through a 100 µm cell strainer. Cells were pelleted at 300 x g for 5 min 
and resuspended in ACK Lysis buffer (Life technologies, Victoria, Australia) to remove red blood 
cells before being counted by a hemocytometer. Aliquots of cell suspension in FACS buffer (PBS 
containing 1% BSA, 2 mM EDTA) were blocked with mouse anti-rat CD32 Fc block for 5 min at 
4°C and incubated with fluorescent-labelled primary antibodies against various immune cells (as 
below) for 30 min at room temperature. Antibodies used included PE-Cy7 labelled mouse anti-rat 
CD45+ to stain for all leucocytes, APC labelled mouse anti-rat CD3 to stain for T lymphocytes and 
PE labelled mouse anti-rat macrophage subset to stain for macrophages with PE labelled isotype 
control.  SYTOX Blue dead cell dye was used to eliminate non-viable cells. Tumour cells were 
identified by mCherry expression and their failure to bind CD45 antibody. Total cell count in the 
lymph node cell suspensions was determined by adding a known volume of the cell suspension into 
BD Trucount tubes. Trucount tubes contain a fixed number of FITC-labelled beads per tube and 
enable a determination of the total number of cells analysed by the flow cytometer versus the total 
number of cells in the entire homogenised sample. 
mCherry expressing cancer cells, antibody-labelled immune cells and D-MTX(OH) 
associated cells were detected by multi-colour fluorescence flow cytometry on a MoFlo® Astrios™ 
(Beckman Coulter, NSW, Australia). The following excitation lasers and bandpass filter sets (nm) 
were used to achieve appropriate spectral separation; 488ex, 525/50em for atto-488; 488ex, 
595/50em for PE; 594ex, 620/30em for mCherry; 561ex, 790/80em for PE-Cy7; 647ex, 671/30em 
for APC. Single colour compensation controls were run for all samples and the data were analysed 
on FlowJo Software (TreeStar Inc., USA). The total D-MTX(OH) content in the supernatant and 
cellular fraction was also quantified by fluorescence detection on a Fluostar OPTIMA plate reader 
(BMG Labtech, Mornington, VIC, Australia). 
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Chemotherapeutic activity of SC and IV administered dendrimers against lymph node metastases 
Popliteal metastases were induced via the injection of MAT 13762 IIIB cells into the right 
footpad of F344 rats as described above. On day 12 and 16 saline vehicle, MTX, D-MTX(OH) or 
D-MTX(OtBu) were administered at a dose of 5 mg/kg MTX equivalents SC into the inner right 
hindlimb just above the heel in a volume of 500 µl/kg body weight, or IV via a lateral tail vein in a 
volume of 500 µl. Rats were sacrificed on day 20 and popliteal lymph nodes removed and weighed 
as an indicator of popliteal tumour burden. To confirm the presence of significant tumour burden 
after 20 days, lymph nodes from 2 saline dosed rats were fixed in 10% formalin and assessed 
histologically as described in the supporting information. Histological evaluation of the lymph 
nodes showed that approximately 95% of the node mass was attributed to tumour tissue and that 
cancer cells were approximately 4 times larger than lymphocytes (supporting information, Figure 
S1). An additional set of popliteal lymph nodes from saline control and SC dosed D-MTX(OH) rats 
were processed for flow cytometry analysis to quantify the number of tumour cells relative to 
immune cells. Detection of cell types was as previously described
23
 with the total cell number 
determined by the addition of a known volume of cell suspension to BD Trucount tubes that contain 
a known number of FITC-labelled fluorescent beads.   
 
Calculation of pharmacokinetic parameters and statistics 
Plasma concentrations were normalised to 5 mg/kg based on the body weight of rats prior to 
dosing and are expressed as ng/ml. Pharmacokinetic parameters were calculated from individual 
plasma concentration versus time profiles as previously described
15
 and values are reported as mean 
± SD (n=3-4). Pharmacokinetic data for D-MTX(OH), D-MTX(OtBu) and D-NH2 after IV 
administration to SD rats were reported previously
20, 24
, and were used here to enable the calculation 
of bioavailability after SC administration. Data from SC lymph-cannulated rats enabled 
determination of the proportion of the dose of dendrimer or MTX that was absorbed via the lymph 
versus via the blood after SC administration. 
Maximum plasma concentrations (Cmax) and time to maximum concentration (Tmax) were 
taken directly from the plasma concentration time curves. Linear regression of the terminal post-
distributive portion of the plasma concentration-time curve was used to determine the plasma 
elimination rate constant (Kel). The area under the plasma concentration-time curves (AUC
0-last
) was 
calculated using the linear trapezoid rule to the last plasma concentration determined (Clast). The 
extrapolated terminal AUC (AUC
last-∞) was calculated from Clast /Kel and was added to the AUC
0-last 
to give total area (AUC
0-∞). Plasma clearance (Cl) was calculated from the dose/AUC0-∞ for the IV 
control group. The bioavailability (percent of the dose absorbed and transported intact into the 
systemic blood) in the SC control group (F) was calculated by dividing the AUCSC by AUCIV and 
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multiplying by 100. In SC lymph cannulated animals the percent bioavailability in blood (Fblood) 
could not be determined for dendrimer dosed animals, since no distinct elimination phase was 
evident by 30 h post dose.  
The plasma concentration-time profiles for MTX, D-MTX(OtBu) and D-NH2 after SC 
administration in lymph-cannulated and non cannulated rats were compared via 2-way ANOVA 
with Bonferroni’s test for least significant differences at each time point. An unpaired T-test was 
used to compare the Cmax and Tmax between lymph cannulated and uncannulated rats. The anticancer 
activity in rats administered MTX, D-MTX(OtBu) or D-MTX(OH) via the IV or SC routes was 
compared to rats administered SC saline vehicle via 1 way AVOVA with a Tukey’s post test for 
least significant differences. Significance was determined as p<0.05.  
 
Results: 
 
Lymphatic transport and biodistribution of dendrimers and methotrexate 
 The dendrimer where 50% of surface groups were PEGylated and 50% left underivatised,  
(D-NH2) was absorbed slowly after SC administration into the inner left heel of rats, reaching peak 
plasma concentrations of approximately 12 µg/ml after 1 day (Figure 2A). Approximately 76% of 
the SC dose was absorbed (Table 1). The organ biodistribution profiles after IV and SC 
administration are shown in Figure 3. The patterns of organ disposition for D-NH2 were similar in 
IV and SC dosed rats and the levels of dendrimer in the organs of SC dosed rats was approximately 
25-50% lower than that in the IV group, presumably reflecting incomplete absorption. The similar 
biodistribution patterns after SC and IV administration are consistent with the fact that the major 
3
H 
species in plasma and lymph (with the exception of liberated monomeric 
3
H-lysine at later time 
points) was intact dendrimer (SEC profiles in Figures S2 & S3, supporting information). The 
biodistribution pattern after SC administration therefore matched the biodistribution pattern of the 
intact dendrimer after IV administration. 
After SC administration to lymph cannulated animals, the fraction of the dose recovered in 
the lymph up to 30 h post dose for D-NH2 was 19% (Figure 4, Table 1). As a result, the plasma 
concentration-time profiles showed lower levels of D-NH2 in the plasma of thoracic lymph duct 
cannulated rats when compared to rats with an intact lymph-blood circuit (Figure 2A). Cmax in 
lymph cannulated rats was significantly lower (4.8 vs 11.9 µg/ml) than that in SC control rats. 
  D-COOH had a similar IV pharmacokinetic profile to that of D-NH2, despite the 
presence of anionic rather than cationic charge on 50% of available surface groups (Figure 2B). The 
SC bioavailability of D-COOH was slightly lower than D-NH2 (59% when compared to 76%, Table 
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1). The organ deposition of D-COOH was similar between IV and SC dosed rats, despite the lower 
SC bioavailability (Figure 3). SEC profiles revealed some breakdown of the dendrimer in plasma 
samples 24-96 hours after SC administration (Figure S2, supporting information). No evidence of 
high molecular weight species was seen after incubation with plasma or after SC dosing, suggesting 
that D-COOH does not bind to plasma proteins. After SC administration of D-COOH to lymph 
cannulated animals approximately 14% of the injected 
3
H dose was recovered in lymph as intact 
dendrimer over 30 h and this did not differ significantly when compared to the lymphatic recovery 
of D-NH2 (Figure 4, Table 1; Figure S3, supporting information). Consistent with the lymphatic 
transport data, the plasma concentration-time profiles of D-COOH in lymph cannulated animals 
were lower than that in non-lymph cannulated rats (Figure 2B), as seen for D-NH2.    
D-MTX(OtBu) was absorbed at a similar rate to D-NH2 and D-COOH, reaching peak 
plasma concentrations of approximately 11.7 µg/ml after 1 day (Figure 2B, Table 1). The fraction of 
the dose absorbed, however, was lower (47%). The pattern of organ biodistribution for D-
MTX(OtBu) after SC administration was again similar to that after IV administration (Figure 3). 
SEC profiles revealed that 
3
H-D-MTX(OtBu) was present in plasma and lymph mainly as high 
molecular weight species that eluted over 18-34 mins (Figure S2 & S3, supporting information). 
This was also the case after intravenous administration for D-MTX(OtBu) and suggests that D-
MTX(OtBu) exists in biological fluids as high molecular weight species, for example aggregates or 
opsonised species
20
. The absorption of D-MTX(OtBu) into the lymph after SC administration to 
lymph cannulated animals was significant (24% of the SC dose of D-MTX(OtBu) was absorbed via 
the lymph over 30 h) resulting in considerably lower plasma levels in lymph cannulated animals 
when compared to control (lymph intact) animals (Figure 4). 
 In contrast to the other dendrimers, plasma levels of D-MTX(OH) were below the level of 
quantification at all times after SC administration. This likely reflected both poor absorption and 
rapid plasma clearance of D-MTX(OH). The absolute fraction of D-MTX(OH) absorbed could 
therefore not be calculated based on the plasma concentration-time profiles. The organ 
biodistribution profiles suggested that approximately 10% of the dose gained access to the systemic 
circulation over 3 days since approximately 10% of the dose was recovered in the liver and spleen 
(Figure 3). Note that almost the entire IV dose of D-MTX(OH) was recovered in the liver and 
spleen after 3 days providing support for the use of this quantity as an indicator of absorption in SC 
dosed animals.
20
 For comparison, the plasma profiles for each dendrimer construct and MTX after 
IV administration are shown in Figure S4 (supporting information). 
 The proportion of an SC dose of D-MTX(OH) that was recovered in thoracic lymph over 30 
h was also lower (5%) than the other dendrimers, however, in light of the low overall absorption a 
large proportion of the absorbed dose was lymphatically transported (Table 1, Figure 4). The SEC 
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profile of D-MTX(OH) in lymph also showed the presence of high molecular weight material 
(supporting information, Figure S3). Incubation of D-MTX(OH) with fresh lymph did not result in 
the formation of the same high molecular weight species, suggesting that the 
3
H-labelled D-
MTX(OH) was absorbed in this form rather than being assembled in lymph. It is not known 
whether this high molecular weight material was formed via interaction with soluble proteins in the 
interstitium or whether it represented dendrimer aggregates.  
 The fraction of the solution formulation of MTX that was absorbed from an SC injection site 
was 74% (consistent with previously reported SC pharmacokinetics in rats and humans
25
). In 
contrast to the dendrimer-based formulations of MTX, absorption occurred almost exclusively via 
the blood, with only 2% of the dose recovered in thoracic duct lymph over 30 h. 
 
Biodistribution of dendrimers and MTX in non-cancerous and tumour burdened lymph nodes 
 Previous studies have shown that D-MTX(OH) is rapidly cleared from the systemic 
circulation by the organs of the MPS
20
, limiting tumour access from the blood via EPR. This 
property, however, might be expected to promote capture by macrophages in lymph nodes after SC 
administration, promoting targeting to sites of lymph metastatic spread. In contrast, D-MTX(OtBu) 
more effectively evades MPS clearance and has increased potential to gain access to lymph nodes 
and lymph resident tumours via EPR. MTX(OtBu) also has the potential to access the lymph (and 
lymph nodes) directly from the injection site.  
The biodistribution of dendrimers and MTX in non-cancerous and tumour burdened lymph 
nodes were therefore examined after IV and SC administration (Figure 5A). SC administration of 
D-NH2, D-COOH or D-MTX(OtBu) led to the retention of approximately 1.3 to 2.6% injected 
dose/g in non-tumour bearing primary (popliteal) and secondary (iliac and inguinal) lymph nodes. 
Retention of dendrimers in tumour burdened popliteal nodes was ~2-3 fold higher (4-7% injected 
dose/g). D-COOH retention in tumour-burdened nodes was not examined since retention in non-
tumour burdened lymph nodes was similar to that of D-NH2. In contrast, the retention of D-
MTX(OH) in non-tumour burdened and tumour-burdened lymph nodes was significantly higher (up 
to 10 fold) than that of D-NH2, D-COOH or D-MTX(OtBu), with approximately 28 to 36% of the 
injected dose retained per gram of lymph node tissue after SC administration, in spite of the 
relatively low overall absorption. This value is also probably a conservative estimate of uptake into 
the popliteal lymph node alone (rather than pooled lymph nodes), since ex vivo fluorescence 
imaging of lymph nodes after injection of atto488-labelled D-MTX(OH) showed higher retention in 
the popliteal lymph node when compared to other nodes (Figure 5B).  
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After IV administration of D-NH2, D-MTX(OtBu) or D-MTX(OH) to rats bearing popliteal 
lymph node metastases, the retention of the dose in the tumour burdened lymph nodes was only 1 to 
2%/g, suggesting that SC administration improved exposure to downstream lymph nodes. The 
retention of MTX in lymph nodes after IV or SC dosing was less than 0.3%/g (not shown), 
suggesting limited lymph node retention for the solution formulation of the drug. 
The mechanisms by which PEGylated dendrimers target tumours and macrophages in MPS 
organs after IV administration is well established. The mechanism by which PEGylated dendrimers 
(in particular D-MTX(OH)) target lymph nodes downstream from an SC injection site or lymph 
node resident metastases is less clear. We therefore sought to examine the patterns of lymph node 
and lymph node metastasis disposition after SC administration of D-MTX(OtBu) and D-MTX(OH).  
To determine whether D-MTX(OH) was retained in lymph nodes as a result of physical 
filtration or via electrostatic interactions with, or internalisation into cells, initial studies examined 
whether the dendrimer was associated with the supernatant or cell pellet following lymph node 
homogenisation. This could not be determined for D-MTX(OtBu) since lymph node retention was 
too low to accurately quantify the 
3
H label in both the cell pellet and supernatant). For D-MTX(OH) 
approximately 96% of the dendrimer in the node 3 days after SC administration was associated with 
the supernatant, and only 4% with the cell pellet. In addition, visualisation of the localisation of 
Atto-488 labelled D-MTX(OH) within whole lymph nodes via confocal fluorescence microscopy 
indicated that the dendrimer was distributed throughout the lymph node (Figure 6A). As expected, 
no fluorescence was detected in the lymph nodes of D-MTX(OtBu) dosed rats (not shown). This 
suggests that in non-tumour bearing lymph nodes, D-MTX(OH) is retained primarily via physical 
filtration, rather than cell association.  
A recent study by Baker and colleagues has suggested that MTX-conjugated dendrimers 
may be internalised into macrophages and cancer cells that overexpress beta and alpha folate 
receptors respectively 
26, 27
. Flow cytometry was therefore used to determine dendrimer (Atto-488 
labelled D-MTX(OH)) association with macrophages and MAT cancer cells in tumour bearing 
lymph nodes 3 days after SC administration. Approximately 20% of MAT 13762 IIIB cells and 
macrophages in lymph nodes were positive for Atto488-labelled D-MTX(OH). In contrast less than 
3% of total leucocytes and T-lymphocytes were positive for dendrimer (Figure 6B). Confocal 
fluorescence microscopy of a section of lymph node tissue also showed that the majority of the Atto 
label (and therefore the dendrimer) was located in the lymph node parenchyma, rather than within 
metastatic foci (Figure 6C), suggesting that D-MTX(OH) targeted macrophages and cancer cells 
surrounding areas of lymph fluid flow rather than in metastatic foci. 
 
Anticancer activity against lymph node metastases of rat breast carcinoma 
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 The anticancer activity of MTX and the MTX-conjugated dendrimers was examined against 
popliteal metastases derived from a primary MAT carcinoma. After the injection of cancer cells into 
the footpad of syngeneic rats, popliteal lymph nodes increased in size from approximately 10 mg at 
the time of first drug dose to approximately 100 mg at day 20 after initiation of the primary tumour.  
To identify whether localised (i.e. SC) administration of the lymph node-targeted D-
MTX(OH) provided therapeutic advantage when compared to IV administration of drug or 
dendrimer, or SC administration of non-lymph node targeted D-MTX(OtBu) or methotrexate, 
anticancer activity was assessed for all MTX preparations after IV and SC administration. SC or IV 
administration of MTX at 5 mg/kg twice over 8 days failed to significantly reduce lymph node 
tumour burden (Figure 7A). In contrast, SC and IV administration of D-MTX(OtBu) and D-
MTX(OH) significantly reduced tumour burden in the lymph node by approximately 30 to 50%. 
Figure 7A shows a trend towards increased anticancer activity for D-MTX(OtBu) after IV 
administration when compared to SC administration (suggesting anticancer activity mainly via 
enhanced permeation and retention of the dendrimer into the microtumour mass). In contrast, D-
MTX(OH) was equally effective after SC and IV administration.  
To confirm that the reduction in popliteal lymph node mass was due to the chemotherapeutic 
activity of methotrexate, FACS analysis of cell populations in the lymph nodes of rats treated with 
saline control or SC D-MTX(OH) revealed that the reduction in popliteal mass was a result of 
reduced numbers of MAT cancer cells and macrophages that typically increase in number with 
tumour growth
28
 (Figure 7B). In contrast, the number of leukocytes remained unchanged between 
control and D-MTX(OH) dosed rats. 
 
Discussion: 
 Metastatic spread of cancer is the major cause of cancer-related death. Surgical intervention 
combined with chemo- and radiation therapies can eradicate much of the tumour burden, however, 
this approach is often not sufficient to remove all cancer cells, including cancer stem cells and 
metastatic nodules.
29, 30
 This can lead to the regrowth of drug resistant tumours that become 
increasingly difficult to treat. Dose related toxicity induced via the systemic administration of 
chemotherapeutic drugs also often prohibits the use of escalating doses, and may preclude the use of 
certain combinations of macromolecular and small molecule therapeutics.
31-33
 In light of these 
complications, there is increasing interest in the localised administration of chemotherapeutics. 
Localised administration has the potential to provide high drug concentrations at the site of tumour 
resection and to promote the killing of tumour cells that persist post surgery (such as at the site of 
glioma removal, where tumour resection is often incomplete 
34
). Local administration may also 
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promote uptake into draining lymphatics, thereby enhancing the elimination of disseminating cancer 
cells in sentinel lymph nodes. In the current study, we have examined the potential utility of 
localised administration of drug-conjugated dendrimers as a means of targeting sites of lymph-
metastatic spread, since dendrimers have previously been shown to preferentially access the 
lymphatics after SC administration when compared with small molecule drugs or PEGylated 
liposomes.
10
  
 Consistent with previous studies of similarly sized doxorubicin-conjugated dendrimers
10
 the 
PEGylated and MTX-conjugated systems explored here were incompletely absorbed after SC 
administration. However, in all cases, a significant proportion of the absorbed dose was taken up 
into the lymphatics from the injection site, and retention in downstream lymph nodes was 
significantly higher than that observed after administration of a solution formulation of 
methotrexate. Although lymphatic targeting was evident with all the dendrimer-based systems, 
notable differences were evident across the three constructs examined. The non drug-conjugated 
dendrimer core (D-NH2) (that comprised a surface with 50% PEG and 50% underivatised amine 
groups) was relatively well absorbed (76% bioavailability) and 19% of the dose was recovered in 
the draining lymphatics up to 30 hr post injection. This was slightly lower than that seen previously 
for a similarly sized, but fully PEGylated (and uncharged), dendrimer where absorption was 
essentially complete and the proportion of the dose recovered in the lymph was 30% over 30 h.
15
 
The incomplete absorption of D-NH2 observed here was likely a function of the interaction of the 
partial positive charge on the dendrimer with the interstitial matrix.
35
 Conjugation of the surface 
amine groups of D-NH2 with either GILGVP-glutamic acid (to give a non drug-conjugated anionic 
control dendrimer, D-COOH), or O-t-butylated or underivatised MTX via the same hexapeptide 
linker to form D-MTX(OtBu) or D-MTX(OH) respectively resulted in further decreases in 
absorption. In the case of D-MTX(OtBu) and D-COOH the reduction was moderate and 
approximately 50% of the dose was absorbed and 25% of the administered dose was transported 
into the lymph for D-MTX(OtBu) and 14% for D-COOH. In contrast, absorption of D-MTX(OH) 
was very low (approximately 10%). This may have resulted from interaction of the polyanionic 
charge associated with the uncapped carboxylic acid of MTX with cationic charge in the 
interstitium
15
, or via interaction with folate or folate-related receptors on cells within the 
interstitium. A complete explanation for this behaviour is not evident at this time although the 
relatively robust absorption and lymphatic transport of D-COOH suggests that a simple charge-
charge interaction in unlikely to completely explain the differential behaviour of D-MTX(OH).  
Although the SC absorption of D-MTX(OH) was low, a significant proportion of the 
absorbed dose was recovered in lymph, and a very large proportion of the absorbed dose was 
retained in the draining lymph nodes. Indeed, after SC administration of D-MTX(OH), recovery in 
Page 17 of 32
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
18 
 
the draining lymph nodes was approximately 10 fold higher than that observed for D-MTX(OtBu), 
D-COOH or D-NH2, in spite of the fact that absorption from the injection site was approximately 5 
fold lower. When comparing SC and IV administration, recovery in the lymph nodes was 
approximately 2-fold higher after SC administration for most dendrimers. For D-MTX(OH), 
however, where lymph node recovery was high after SC administration, the difference was more 
profound and lymph node recovery was increased approximately 20 fold after SC administration. 
Lymph node recovery was very low after both SC and IV administration of the MTX solution. 
In comparison to MTX alone, D-MTX(OtBu) and D-MTX(OH) therefore provided 
markedly different disposition profiles. D-MTX(OtBu) resulted in prolonged plasma exposure after 
SC and IV dosing, enhanced lymphatic exposure and enhanced lymph node retention after IV (3-5 
fold) and SC (10-20 fold) administration when compared to MTX. In contrast, D-MTX(OH) 
resulted in limited plasma exposure after IV administration and very low plasma exposure after SC 
administration. Absolute lymphatic recovery after SC administration was higher than that of MTX, 
but approximately 4 fold lower than that of D-MTX(OtBu). After IV administration lymph node 
recovery was similar to that of D-MTX(OtBu) and therefore moderately (approximately 5 fold) 
higher that that after IV administration of MTX. Notably, however, after SC administration, lymph 
node retention for D-MTX(OH) was very high (approximately 100 fold higher than for MTX).  
Subsequent studies therefore sought to evaluate the impact of the differing disposition 
profiles of the MTX dendrimers on chemotherapeutic activity in a syngeneic model of metastatic 
cancer. In all cases, administration of dendrimer-MTX resulted in more effective inhibition of the 
growth of lymph node metastases when compared to MTX alone, consistent with previous studies 
in a non-metastatic xenograft model.
20
 Surprisingly, however, in spite of the increase in lymph node 
recovery of both dendrimers after SC administration when compared to IV administration, the 
reduction in lymph node mass was no higher after SC administration, and in fact for D-MTX(OtBu) 
activity was moderately (although insignificantly) higher after IV administration. The data were 
particularly surprising for D-MTX(OH) where lymph node recovery was very high, but where, 
activity was not improved.  
In an attempt to better understand the high recovery of D-MTX(OH) in lymph nodes and 
potentially to provide an explanation for the disconnect between lymph node disposition and 
activity against lymph node resident metastatic cancer, a series of experiments were undertaken to 
evaluate the patterns of dendrimer disposition within lymph nodes and tumour burdened lymph 
nodes. These data suggested that whilst recovery of D-MTX(OH) in lymph nodes was high, the 
dendrimer was present in large part (>90%) in the supernatant of lymph node homogenate, and was 
not internalised into lymph node resident cells. Confocal fluorescence microscopy of tumour 
bearing lymph nodes after SC administration of Atto-488 labelled D-MTX(OH) also showed that 
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the majority of the retained dose was located within the lymph node parenchyma and not within the 
metastatic foci. As such only limited colocalisation of Atto-488 labelled D-MTX(OH) with 
mCherry labelled tumour cells (and more importantly, the centre of the tumour mass) was apparent. 
FACS analysis of a mixed population of cells obtained from a lymph node with metastatic invasion 
also suggested that although cellular interaction of D-MTX(OH) with MAT13762 IIIB cells and 
macrophages was higher than that of lymph node resident leucocytes (consistent with the recent 
suggestion that MTX-conjugated dendrimers may be internalised into macrophages and cancer cells 
that overexpress beta and alpha folate receptors respectively 
26, 27
), the degree of cellular association 
was relatively low (~20% of tumour cells and macrophages were positive for the fluorescently 
labelled dendrimer). It seems likely therefore that whilst macrophages play a role in the retention of 
D-MTX(OH) in MPS organs after IV administration, after SC administration, retention in the 
lymph nodes appears to be driven largely via a physical interaction with the lymph node 
parenchyma, with a more minor component associated with cellular/macrophage targeting. The lack 
of significant colocalisation of D-MTX(OH) with metastatic foci in lymph nodes is also consistent 
with the poor correlation between high levels of lymph node retention of D-MTX(OH) and activity 
against metastatic tumours. It seems likely therefore that the high level of lymph node retention of 
D-MTX(OH) after SC administration was not productive with respect to tumour killing, since the 
dendrimer was not distributed to the centre of metastatic nodules. This likely precluded effective 
release of MTX from D-MTX(OH) via extracellular matrix metalloprotease 2 (MMP2), since 
sequestration in the lymph node occurred at a site distant from the tumour and therefore at a site 
where MMP levels were expected to be low, leading to incomplete drug release. It is also possible 
that MMP2 mediated drug cleavage within the lymph node may be saturated at only low levels of 
dendrimer. This is consistent with the similar anticancer activity of SC administered D-MTX(OH) 
and D-MTX(OtBu), despite significant differences in lymph node retention. It might be expected, 
therefore, that by employing a more labile chemical linker or a tumour that expresses higher levels 
of MMP2, MTX liberation may be more efficient. Under these circumstances, released MTX may 
be able to convect through the lymph node, resulting in increased anticancer activity, even in the 
absence of absolute colocalisation of the dendrimer with metastatic foci.  
In summary, the results of this study show differential patterns of lymphatic uptake and 
lymph node disposition for PEGylated MTX dendrimers after SC and IV administration that were 
dependent upon the chemical properties of the conjugated drug. Conjugation of MTX to the surface 
of the dendrimer significantly reduced absorption from SC injection sites, but also resulted in very 
efficient targeting to draining lymph nodes. These effects were attenuated by OtBu capping of the 
MTX carboxylic acid, which resulted in improved absorption and enhanced long circulation 
properties, but less effective lymph node retention. Both MTX-conjugated dendrimers resulted in 
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improved activity against lymph node resident metastases (when compared to MTX alone), but 
correlation of lymph node retention with anticancer activity was poor and indeed activity was 
similar after IV administration and SC administration, whereas lymph node deposition was far more 
effective after SC administration. In the case of D-MTX(OH) (which was poorly absorbed after SC 
administration, but highly retained in lymph nodes) this likely reflected dendrimer sequestration 
within areas of the lymph node that were not directly associated with metastatic invasion, despite 
efficient retention by cancer cells and lymph node resident macrophages. This in turn might be 
expected to either reduce drug liberation from the dendrimer (since the releasing technology relies 
on the presence of MMPs) or provide a diffusional distance between the site of drug release and 
drug activity that is too great to allow useful activity. Subsequent studies will attempt to better 
harness the lymph node targeting capabilities of PEGylated dendrimers and explore the means by 
which drug disposition into metastatic sites within lymph node tumours can be enhanced.  
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Figures: 
 
 
 
 
Figure 1. Structure of G5 methotrexate-conjugated dendrimers - D-MTX(OH) and D-MTX(OtBu). 
The surface comprised 32 lysine residues conjugated with PEG1100 at the ε-amino group and 
GILGVP-MTX (α-carboxyl capped or uncapped) at α-amino groups. The constructs have been 
previously described and characterized.
20
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Figure 2. Plasma concentration-time profiles of D-NH2 (Panel A), D-COOH (Panel B), D-
MTX(OtBu) (Panel C) and MTX (Panel D) after IV and SC administration at 5 mg/kg to rats. 
Closed symbols represent IV plasma profiles, open symbols represent control SC plasma profiles 
and grey symbols represent SC plasma profiles in thoracic lymph duct cannulated animals. Data 
represents mean ± s.d. (n=3-5). * represents significantly lower plasma concentrations in lymph 
cannulated rats when compared to SC control rats at each time point indicated by the bar. 
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Figure 3: Organ biodistribution of D-NH2 (Panel A, 120 h), D-COOH (Panel B, 120 h), D-
MTX(OtBu) (Panel C, 120 h) and D-MTX(OH) (Panel D, 72 h) after IV (solid bars) or SC (open 
bars) administration of 5 mg/kg dendrimer to rats. Data represents mean ± s.d. (n=3). 
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Figure 4. Cumulative recovery of D-MTX(OtBu) (closed circles), D-MTX(OH) (grey circles), D-
NH2 (open circles), D-COOH (closed triangles) or methotrexate (open triangles) in thoracic lymph 
after SC administration into the left inner heel of rats. Data represents mean ± s.d. (n=3-5). 
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Figure 5. Panel A - Dendrimer uptake into pooled primary and secondary lymph nodes in non-
tumour bearing rats after SC administration into the inner heel or primary (popliteal) tumour 
burdened lymph nodes after SC or IV administration. Data represents mean ± s.d. (n=3-5). * 
indicates p<0.001 vs. other dendrimers; 
#
 indicates p<0.001 vs. IV administration. ND – not 
determined since biodistribution in normal lymph nodes was similar to D-MTX(OtBu) and D-NH2. 
Panel B - Ex vivo fluorescence imaging of lymph nodes 3 days after SC injection of D-MTX(OH) 
into the inner ipsilateral heel to primary tumour growth on a Caliper IVIS II in vivo imager.  
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Figure 6. (A) Confocal fluorescent image (4X) of Atto488 labelled D-MTX(OH) in a popliteal 
lymph node 3 days after SC administration into the heel. (B) Proportion of cells within a tumour-
bearing lymph node that were positive for Atto488-labelled D-MTX(OH) 3 days after SC 
administration into the inner heel of rats bearing micrometastases of MAT carcinoma. Data 
represents mean ± s.d (n=3-6). (C) Confocal fluorescent image (10X) of a popliteal lymph node 
bearing mCherry-expressing MAT micrometastases 3 days after SC injection of Atto488 labelled 
D-MTX(OH) into the inner heel of rats. Red signal is from the mCherry expressing MAT cells and 
the green signal is from the Atto488 label. 
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Figure 7. (A) Antitumour efficacy of MTX or MTX-conjugated dendrimers after SC administration 
into the inner left heel or IV administration against popliteal lymph node-resident metastases of 
MAT 13762 IIIB carcinoma. Dendrimers or MTX were given twice over an 8 day period beginning 
12 days after the footpad injection of cancer cells. The dashed line indicates the typical mass of 
lymph nodes before administration of the first dose. Data represents mean ± s.e.m (n=4-7). 
*Indicates p<0.05 cf. saline control dosed rats. (B) Difference in lymph node cell numbers after 
treatment of rats bearing popliteal lymph node-resident metastases of MAT 13762 IIIB carcinoma 
with SC D-MTX(OH) over an 8 day period when compared to cell numbers in the popliteal lymph 
node of rats treatment with saline vehicle alone. Data represents mean ± s.d. (n=3). Data for Panel B 
was generated in a separate group of rats to Panel A, but terminal popliteal lymph node masses did 
not differ significantly for either saline or SC D-MTX(OH) dosed animals between the two groups 
of rats. 
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Tables: 
 
Table 1. Pharmacokinetic parameters for IV and SC dosed dendrimers and MTX after 
administration of 5 mg/kg to rats. Data represents mean ± s.d. (n=3-5). 
 
  MTX D-NH2 D-MTX(OH) D-MTX(OtBu) D-COOH 
 IV control  
k h
-1
 0.43 ± 0.09 0.02 ± 0.00 2.63 ± 0.55 0.02 ± 0.00 0.02 ± 0.00 
AUC0-∞ µg/ml.h 5.9 ± 0.2 1923 ± 210 74 ± 5 2734 ± 161 1769 ± 45 
Cl ml/h 218 ± 5 0.8 ± 0.1 20 ± 3.3 0.5 ± 0.0 0.8 ± 0.0 
 SC control  
k h-1 0.34 ± 0.09 0.01 ± 0.00 ND 0.01 ± 0.00 0.02 ± 0.00 
AUC 0-∞ µg/ml.h 4.4 ± 0.5 1463 ± 607 ND 1247 ± 342 1034 ± 29 
Tmax h 0.5 ± 0.0 23 ± 8 ND 21 ± 10 24 ± 0 
Cmax µg/ml 3.0 ± 0.3 11.9 ± 1.2 ND 11.7 ± 3.4 13.2 ± 1.8 
F % 74 ± 8.6 76 ± 32 ND 47 ± 13 59 ± 2 
 SC lymph cannulated  
k h
-1
 0.30 ± 0.08 ND ND ND ND 
Tmax h 0.4 ± 0.1 17 ± 9 ND 26 ± 3 27 ± 3 
Cmax µg/ml 2.7 ± 1.3 4.8 ± 1.6* ND 2.7 ± 2.5* 2.3 ± 1.2* 
Flymph % 2 ± 1 19 ± 4 5 ± 2 24 ± 3 14 ± 1 
ND – not determined due to the absence of an elimination phase in the plasma profile to 30 h or 
rapid plasma clearance following absorption 
*Represents a significant difference compared to the equivalent parameter in the SC control group. 
 
Page 31 of 32
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
  
 
 
 
80x48mm (300 x 300 DPI)  
 
 
Page 32 of 32
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
